frontiers | Frontiers in Immunology

TYPE Correction
PUBLISHED 12 December 2025
DOI 10.3389/fimmu.2025.1761643

OPEN ACCESS

APPROVED BY
Frontiers Editorial Office,
Frontiers Media SA, Switzerland

*CORRESPONDENCE
Frontiers Production Office
production.office@frontiersin.org

RECEIVED 05 December 2025
ACCEPTED 05 December 2025
PUBLISHED 12 December 2025

CITATION
Frontiers Production Office (2025) Correction: Tumor-penetrating peptide boosts bispecific T-cell engager antitumor efficacy for the pancreatic cancer. *Front. Immunol.* 16:1761643. doi: 10.3389/fimmu.2025.1761643

Correction: Tumor-penetrating peptide boosts bispecific T-cell engager antitumor efficacy for the pancreatic cancer

Frontiers Production Office*

Frontiers Media SA, Lausanne, Switzerland

KEYWORDS

KRAS G12V, bispecific T-cell engager (BiTE), IRGD, pancreatic cancer, T-cell infiltration

A Correction on

Tumor-penetrating peptide boosts bispecific T-cell engager antitumor efficacy for the pancreatic cancer

By Zou L, Chen J, Bai X, Wang Y, Lu C, Wang Q, Tuerhong S, Li M, Zheng Q, Meng F and Du J (2025) *Front. Immunol.* 16:1693755. doi: 10.3389/fimmu.2025.1693755

The Editor Christian Klein's affiliation "Ludwig Maximilian University of Munich, Germany" was erroneously given as "Roche Innovation Center Zurich, Switzerland".

The original version of this article has been updated.